121 related articles for article (PubMed ID: 36099446)
21. Self-assembling prodrug nanotherapeutics for synergistic tumor targeted drug delivery.
Wang Z; Chen J; Little N; Lu J
Acta Biomater; 2020 Jul; 111():20-28. PubMed ID: 32454086
[TBL] [Abstract][Full Text] [Related]
22. Integrin-targeting disulfide-crosslinked micellar docetaxel eradicates lung and prostate cancer patient-derived xenografts.
Ni D; Guo B; Zhong Z; Chen Y; Yang G; Yang J; Zhong Z; Meng F
Acta Biomater; 2023 Oct; 170():228-239. PubMed ID: 37634830
[TBL] [Abstract][Full Text] [Related]
23. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation.
Hu C; Huang Y; Chen Y
Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418
[TBL] [Abstract][Full Text] [Related]
24. Targeting prostate cancer cells with hybrid elastin-like polypeptide/liposome nanoparticles.
Zhang W; Song Y; Eldi P; Guo X; Hayball JD; Garg S; Albrecht H
Int J Nanomedicine; 2018; 13():293-305. PubMed ID: 29391790
[TBL] [Abstract][Full Text] [Related]
25. Fabrication of self-assembled peptide nanoparticles for in vitro assessment of cell apoptosis pathway and in vivo therapeutic efficacy.
Rizvi SFA; Mu S; Zhao C; Zhang H
Mikrochim Acta; 2022 Jan; 189(2):53. PubMed ID: 34999971
[TBL] [Abstract][Full Text] [Related]
26. Active targeting redox-responsive mannosylated prodrug nanocolloids promote tumor recognition and cell internalization for enhanced colon cancer chemotherapy.
Gao Y; Qiu W; Liang M; Ma X; Ye M; Xue P; Kang Y; Deng J; Xu Z
Acta Biomater; 2022 Jul; 147():299-313. PubMed ID: 35640802
[TBL] [Abstract][Full Text] [Related]
27. Bilirubin Nanoparticle-Assisted Delivery of a Small Molecule-Drug Conjugate for Targeted Cancer Therapy.
Lee S; Lee Y; Kim H; Lee DY; Jon S
Biomacromolecules; 2018 Jun; 19(6):2270-2277. PubMed ID: 29712433
[TBL] [Abstract][Full Text] [Related]
28. The conjugates of forky peptides and nonsteroidal anti-inflammatory drugs (NSAID) self-assemble into supramolecular hydrogels for prostate cancer-specific drug delivery.
Tao M; He S; Liu J; Li H; Mei L; Wu C; Xu K; Zhong W
J Mater Chem B; 2019 Jan; 7(3):469-476. PubMed ID: 32254734
[TBL] [Abstract][Full Text] [Related]
29. iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability.
Gao F; Zhang J; Fu C; Xie X; Peng F; You J; Tang H; Wang Z; Li P; Chen J
Int J Nanomedicine; 2017; 12():4147-4162. PubMed ID: 28615942
[TBL] [Abstract][Full Text] [Related]
30. Preparation and evaluation of tumour microenvironment response multistage nanoparticles for epirubicin delivery and deep tumour penetration.
Dai J; Han S; Ju F; Han M; Xu L; Zhang R; Sun Y
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):860-873. PubMed ID: 29771149
[TBL] [Abstract][Full Text] [Related]
31. Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer.
Yallapu MM; Khan S; Maher DM; Ebeling MC; Sundram V; Chauhan N; Ganju A; Balakrishna S; Gupta BK; Zafar N; Jaggi M; Chauhan SC
Biomaterials; 2014 Oct; 35(30):8635-48. PubMed ID: 25028336
[TBL] [Abstract][Full Text] [Related]
32. Dual-peptide-functionalized albumin-based nanoparticles with ph-dependent self-assembly behavior for drug delivery.
Chen B; He XY; Yi XQ; Zhuo RX; Cheng SX
ACS Appl Mater Interfaces; 2015 Jul; 7(28):15148-53. PubMed ID: 26168166
[TBL] [Abstract][Full Text] [Related]
33. Peptide-Conjugated Nanoparticles as Targeted Anti-angiogenesis Therapeutic and Diagnostic in Cancer.
Rajabi M; Adeyeye M; Mousa SA
Curr Med Chem; 2019; 26(30):5664-5683. PubMed ID: 31250748
[TBL] [Abstract][Full Text] [Related]
34. Design of integrin α
Lv X; Zhang C; Shuaizhen Q; Yu R; Zheng Y
Biomed Pharmacother; 2020 Aug; 128():110236. PubMed ID: 32447209
[TBL] [Abstract][Full Text] [Related]
35. Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors.
Arosio D; Manzoni L; Corno C; Perego P
Recent Pat Anticancer Drug Discov; 2017; 12(2):148-168. PubMed ID: 28164756
[TBL] [Abstract][Full Text] [Related]
36. Peptide targeted lipid nanoparticles for anticancer drug delivery.
Pearce TR; Shroff K; Kokkoli E
Adv Mater; 2012 Jul; 24(28):3803-22, 3710. PubMed ID: 22674563
[TBL] [Abstract][Full Text] [Related]
37. Tailor-made legumain/pH dual-responsive doxorubicin prodrug-embedded nanoparticles for efficient anticancer drug delivery and in situ monitoring of drug release.
Li Y; Niu Y; Zhu J; Gao C; Xu Q; He Z; Chen D; Xu M; Liu Y
Nanoscale; 2020 Jan; 12(4):2673-2685. PubMed ID: 31942900
[TBL] [Abstract][Full Text] [Related]
38. Biomimetic peptide display from a polymeric nanoparticle surface for targeting and antitumor activity to human triple-negative breast cancer cells.
Bressler EM; Kim J; Shmueli RB; Mirando AC; Bazzazi H; Lee E; Popel AS; Pandey NB; Green JJ
J Biomed Mater Res A; 2018 Jun; 106(6):1753-1764. PubMed ID: 29424479
[TBL] [Abstract][Full Text] [Related]
39. Ligand-Modified Erythrocyte Membrane-Cloaked Metal-Organic Framework Nanoparticles for Targeted Antitumor Therapy.
Lin Y; Zhong Y; Chen Y; Li L; Chen G; Zhang J; Li P; Zhou C; Sun Y; Ma Y; Xie Z; Liao Q
Mol Pharm; 2020 Sep; 17(9):3328-3341. PubMed ID: 32804508
[TBL] [Abstract][Full Text] [Related]
40. Reactive oxygen species and glutathione dual responsive nanoparticles for enhanced prostate cancer therapy.
Zhang L; Zhang S; Li M; Li Y; Xiong H; Jiang D; Li L; Huang H; Kang Y; Pang J
Mater Sci Eng C Mater Biol Appl; 2021 Apr; 123():111956. PubMed ID: 33812584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
